• In early August 2026, Merck reported higher second-quarter sales and slightly raised its 2026 revenue guidance, while also highlighting new approvals and pipeline progress in oncology, cardiovascular disease and RSV prevention.
• These updates underline how Merck is broadening its portfolio beyond KEYTRUDA, adding fresh revenue drivers across human health and animal health as it prepares for future patent challenges.
• We’ll now examine how Merck’s raised 2026 sales guidance and recent product milestones influence its existing investment narrative and future earnings debate.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Merck Investment Narrative Recap

To own Merck today, you need to believe that its expanding pipeline and new product launches can offset KEYTRUDA’s eventual loss of exclusivity, even as near term earnings are weighed down by acquisition charges and higher R&D. The latest guidance raise suggests management’s confidence in 2026 sales, while the key short term debate remains how quickly newer franchises like vaccines, cardiometabolic drugs and Animal Health can scale against pricing pressure and product concentration risk.

Within that context, the move to broaden ENFLONSIA’s RSV indication in both the U.S. and EU feels particularly relevant. It reinforces the idea that Merck is building a second wave of vaccine and prevention assets that sit alongside newer therapies such as oral PCSK9 inhibitor LIPFENDRA and oncology additions, creating multiple levers that could matter as the market reassesses Merck’s earnings power beyond KEYTRUDA and weighs the durability of its raised 2026 revenue outlook.

Yet while Merck’s broadening portfolio looks reassuring, investors should also be aware that concentrated exposure to oncology and cardiometabolic products could still...

Merck's narrative projects $74.9 billion revenue and $22.0 billion earnings by 2029.

Uncover how Merck's forecasts yield a $136.85 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts, who were previously penciling in revenues near US$79.6 billion and earnings above US$26 billion by 2029, assume Merck’s late stage pipeline and vaccines like ENFLONSIA will more than compensate for KEYTRUDA concentration risk, while others see that same reliance on oncology and cardiometabolic drugs as a key vulnerability, so this new RSV update could shift how you weigh those very different stories.

Explore 8 other fair value estimates on Merck - why the stock might be worth 19% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Merck research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.
• Our free Merck research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merck's overall financial health at a glance.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.